These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 11181665

  • 1. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
    Fleming GF, Fowler JM, Waggoner SE, Copeland LJ, Greer BE, Horowitz I, Sutton G, Schilder RJ, Fracasso PM, Ball HG, McGuire WP.
    J Clin Oncol; 2001 Feb 15; 19(4):1021-9. PubMed ID: 11181665
    [Abstract] [Full Text] [Related]

  • 2. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
    Nagao S, Nishikawa T, Hanaoka T, Kurosaki A, Iwasa N, Hasegawa K, Fujiwara K.
    Jpn J Clin Oncol; 2014 Nov 15; 44(11):1040-4. PubMed ID: 25183770
    [Abstract] [Full Text] [Related]

  • 3. [A pilot study of combined chemotherapy with paclitaxel, doxorubicin and cisplatin for endometrial cancer].
    Honma H, Sagae S, Terasawa K, Tanaka R, Chida M, Mizumoto H, Ishioka S, Saito T, Kudo R.
    Gan To Kagaku Ryoho; 2004 Apr 15; 31(4):549-53. PubMed ID: 15114698
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    O'Reilly S, Fleming GF, Barker SD, Walczak JR, Bookman MA, McGuire WP, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky EK.
    J Clin Oncol; 1997 Jan 15; 15(1):177-86. PubMed ID: 8996140
    [Abstract] [Full Text] [Related]

  • 5. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM, Morris M, Burke TW, Levenback C, Wolf J, Lee JJ, Thall PF, Atkinson EN, Silva EG, Wharton JT.
    Cancer; 1999 Dec 01; 86(11):2291-300. PubMed ID: 10590370
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: Results from GOG 184.
    Cella D, Huang H, Homesley HD, Montag A, Salani R, De Geest K, Lee R, Spirtos NM.
    Gynecol Oncol; 2010 Dec 01; 119(3):538-42. PubMed ID: 20863554
    [Abstract] [Full Text] [Related]

  • 12. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
    Duska LR, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre JF, Klein A, Atkinson T, Seiden MV, Campos S.
    Gynecol Oncol; 2005 Jan 01; 96(1):198-203. PubMed ID: 15589601
    [Abstract] [Full Text] [Related]

  • 13. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial.
    Soper JT, Reisinger SA, Ashbury R, Jones E, Clarke-Pearson DL.
    Gynecol Oncol; 2004 Oct 01; 95(1):95-100. PubMed ID: 15385116
    [Abstract] [Full Text] [Related]

  • 14. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study.
    McMeekin DS, Walker JL, Hartenbach EM, Bookman MA, Koh WJ, Gynecologic Oncology Group.
    Gynecol Oncol; 2009 Jan 01; 112(1):134-41. PubMed ID: 18962846
    [Abstract] [Full Text] [Related]

  • 15. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
    Hitt R, Hornedo J, Colomer R, Mendiola C, Brandariz A, Sevilla E, Alvarez-Vicent J, Cortés-Funes H.
    Semin Oncol; 1995 Dec 01; 22(6 Suppl 15):50-4. PubMed ID: 8643971
    [Abstract] [Full Text] [Related]

  • 16. A phase I study of paclitaxel, doxorubicin, and cisplatin in patients with previously untreated epithelial ovarian cancer.
    Naumann RW, Alvarez RD, Omura GA, Segars E, Kilgore LC, Partridge EE.
    Gynecol Oncol; 1998 Dec 01; 71(3):450-3. PubMed ID: 9887248
    [Abstract] [Full Text] [Related]

  • 17. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ, Elson P, Dreicer R, Hahn R, Nichols CR, Williams R, Einhorn LH.
    J Clin Oncol; 1994 Mar 01; 12(3):483-8. PubMed ID: 7509853
    [Abstract] [Full Text] [Related]

  • 18. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.
    Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, Kline R, Burger RA, Goodman A, Burks RT.
    J Clin Oncol; 2004 Jun 01; 22(11):2159-66. PubMed ID: 15169803
    [Abstract] [Full Text] [Related]

  • 19. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
    Herben VM, Panday VR, Richel DJ, Schellens JH, van der Vange N, Rosing H, Beusenberg FD, Hearn S, Doyle E, Beijnen JH, ten Bokkel Huinink WW.
    J Clin Oncol; 1999 Mar 01; 17(3):747-55. PubMed ID: 10071262
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study.
    Sparano JA, Hu P, Rao RM, Falkson CI, Wolff AC, Wood WC.
    J Clin Oncol; 1999 Dec 01; 17(12):3828-34. PubMed ID: 10577856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.